Zanzalintinib (XL092) plus atezolizumab versus regorafenib in previously treated MSS/MSI-low metastatic colorectal cancer (mCRC): The randomized phase 3 STELLAR-303 study
Saeed, A., Tabernero, J., Wang, G., Ma, X., Smith, R., & Hecht, J. (2024). Zanzalintinib (XL092) plus atezolizumab versus regorafenib … Read More